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THE ANTITUMOR EFFICACY OF CISPLATIN IN COMBINATION 
WITH TRIPTORELIN AND EXEMESTANE THERAPY FOR AN OVARIAN 
CANCER ASCITES MODEL IN WISTAR RATS
I.G. Tkalia*, L.I. Vorobyova, A.N. Grabovoy, V.S. Svintsitsky, T.О. Tarasova
National Cancer Institute, Kyiv 03022, Ukraine
Aim: To study antitumor activity of triptorelin — agonist of gonadotropin-releasing hormone and exemestane — inhibitor of aromatase 
in combination with cisplatin on the model of receptor-positive for estrogens and progesterone malignant transplantable ascites ova rian 
tumor (OT);  to assess tumor response to treatment and VEGF expression in tumor cells under different combinations of cytostatic 
and hormonal drugs. Materials and Methods: 36 female Wistar rats, which underwent intraperitoneal transplantation of ascites OT 
(5×106 cells per animal), have been involved in the study. Rats were distributed into 4 groups (9 rats in each group): group 1 — animals, 
which received combination of cisplatin and triptorelin; group 2 — rats treated with combination of cisplatin and exemestane; group 3 — 
animals, which were administered with combination of cisplatin, triptorelin and exemestane; group 4 — rats, which received combina-
tion of triptorelin and exemestane. Histological study with assessment of treatment pathomorphosis in OT and immunohistochemical 
study have been carried out to analyze VEGF expression in OT cells. Survival of animals has been evaluated. Results: Combination 
of cytostatic agent with triptorelin or exemestane has demonstrated significantly higher rates of treatment pathomorphosis (10.1 ± 0.1% 
and 16.2 ± 0.3%, respectively) and antiangiogenic activity in OT (21.4 ± 1.4% and 15.0 ± 1.3%, respectively), as well as the highest 
survival of animals (100.0 and 85.7%, respectively) as compared with the same in rats treated in regimen of monotherapy with cispla-
tin, triptorelin, exemestane or by combination of hormonal drugs. Among animals treated by combination of cytostatic drug with 
triptorelin, two were cured (22.2%), and among rats, which received cisplatin and exemestane, one animal (11.1%) was cured. Conclu-
sions: Triptorelin and exemestane increase antitumor activity of cisplatin in respect to the transplantable malignant ascites OT and 
significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination.
Key Words: transplantable ascites ovarian tumor, rat, cisplatin, agonist of gonadotropin-releasing hormone triptorelin, inhibitor 
of aromatase exemestane, treatment pathomorphosis, VEGF, survival.
At present, hormonal factors take a significant role 
in the pathogenesis of ovarian cancer (OC). Continuous 
ovulation resulting from reduction of number of preg-
nancies and deliveries in women, infertility of different 
genesis and application of medical drugs stimulating 
ovulation are referred to those factors. However, hor-
monal factors represent a part in complex mechanism 
of endocrine-metabolic and molecular-genetic disor-
ders [1–5]. The results of many studies have shown 
that OC has excessive heterogenicity of molecular-
biological markers and their complex interaction with 
factors of microenvironment including the factor of neo-
angiogenesis (vascular endothelial growth factor — 
VEGF) [6–8]. Treatment effectiveness in OC patients 
is significantly dependent on the molecular-biologic 
characteristics of the tumor [9]. The problems of hor-
mone-dependence of OC and hormonal therapy use 
for this category of patients are still disputable at pre-
sent time. In the previous article we demonstrated data 
of study of animals with transplantable malignant ascites 
estrogen and progesterone receptor-positive ovarian 
tumor (OT) treated in regimen of cisplatin, triptorelin 
and exemestane monotherapy [10]. We have shown 
that among rats, which were treated in monotherapy 
regimen, the strongest antiangiogenic activity in cells 
of OT has been determined with use of hormonal drugs, 
at the same time, the highest level of treatment patho-
morphosis in OT — histological tumor response — has 
been observed at treatment with cisplatin [10]. Sur-
vival of animals treated with cisplatin was higher, than 
the same in rats treated with hormonal drugs; however, 
differences were not significant [10]. In the following 
article, we will present the results of study of animals 
with transplantable OT, which were treated with combi-
nation of cisplatin and hormonal drugs — triptorelin and 
exemestane. Also we will compare the results of treat-
ment of animals in monotherapy regimen and with use 
of combination of these agents.
Aim of study — to investigate antitumor acti-
vity of agonist of gonadotropin-releasing hormone 
( Gn-RH) — triptorelin and aromatase inhibitor — 
exeme stane in combined use with cisplatin on the mo-
del of transplantable malignant ascites estrogen and 
progesterone receptor-positive OT; to evaluate treat-
ment pathomorphosis and VEGF expression in tumor 
cells using different combinations of cytostatic agent 
and hormonal drugs; to compare the results in treat-
ment of rats with the use of both monotherapy and 
combined treatment by mentioned agents.
MATERIALS AND METHODS
Animals. 36 female Wistar rats (130–150 g b. w.) 
bred in the vivarium of R.E. Kavetsky Institute of Ex-
perimental Pathology, Oncology and Radiobiology, 
NAS of Ukraine (Kyiv, Ukraine) have been involved 
in the experiment. All procedures have been carried 
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out in accordance with the recommendations for 
conducting the medical-biological studies with use 
of laboratory animals.
Model of tumor — strain of ascites malignant 
OT. Characteristics of tumor and methods of transplan-
tation of OT to the animals were described earlier [10]. 
Transplantable ascitic liquid was immunocytochemi-
cally tested for the determination of expression of ste-
roid hormones receptors in the tumor cells.
Immunocytochemical analysis of the expres-
sion of estrogens (ERs) and progesterone receptors 
(PRs) in the cells of transplantable OT has been carried 
out in accordance with conventional strategy using 
monoclonal antibodies specific to the ER — anti-Rat 
Estrogen Receptor α (Clone 6F11, Thermo Scientific, 
USA), PR — anti-Rat Progesterone Receptor (Clone 
PR-AT 4.14, Thermo Scientific, USA). For the total 
assessment of ERs, PRs expression in OT, method 
applied by us earlier has been used [10].
Therapy. Cisplatin (P) has been used as solution 
for injection (0.5 mg/ml in 100 ml). Triptorelin (T) was 
used in the form of dry substance of triptorelin acetate 
0.1 mg + mannite 10 mg and solvent in the form of so-
dium chloride 0.9% 1 ml. Exemestane (E) was applied 
in the form of pills, 1 pill contains 25 mg of exemestane. 
Treatment with exemestane was started on the day 
of transplantation and has been carried out during 
10 days, with cisplatin and triptorelin — 48 hours 
after transplantation during 5 days. Treatment drugs 
were applied to animals in treatment doses according 
to the current method recommendations and data 
of previously conducted studies [10].
Rats were divided into 4 groups, 9 rats in each 
group (Table 1).
Table 1. Groups of animals according to treatment regimen 
Animals, n = 36 Treatment
Group 1 
(Р + Т), 
n=9
Combination of cisplatin and triptorelin.
Cisplatin intraperitoneally 1.0 mg/kg — 0.15 mg/
rat·day-1 or 0.3 ml + 0.3 ml of physiological solution/
rat·day-1 during 5 days.
Triptorelin intramuscularly 0.1 mg/rat·day-1 for 5 days
Group 2 
(Р+Е), 
n=9
Combination of cisplatin (in the doses mentioned above 
during 5 days) and exemestane.
Exemestane orally 12.5 mg (100 mkg/kg) + 0.5 ml physi-
ological solution/rat·day-1 during 10 days
Group 3 
(Р + Т + Е), 
n=9
Combination of cisplatin (during 5 days), triptorelin (for 
5 days) and exemestane (during 10 days) in the doses 
mentioned above
Group 4 
(Т + Е), n=9
Combination of triptorelin (during 5 days) and exemes-
tane (for 5 days) in the doses mentioned above
Observation has been started in 24 hours after 
the last injection of exemestane. Died or euthanized 
animals underwent autopsy for macroscopic evalua-
tion of tumor process spread and pathological changes 
of internal organs. Cancer-changed organs of peritone-
al cavity and pelvis of rats were removed for histological 
and immunohistochemical studies. In order to evaluate 
dynamics of tumor process objectively, studied animals 
were euthanized by one rat from each group through 
decapitation on 14th, 17th and 19th day of observation. 
Moreover, macroscopic study of internal organs in intact 
rats was carried out for the objective analysis of patho-
logical changes in organs of peritoneal cavity and pelvis 
of the studied animals. Antitumor effect was evaluated 
as presented earlier [10].
Toxic effect of antitumor drugs has been assessed 
by degrowth of spleen (indirect signs of total and he-
matological toxicity), which was weighed on torsion 
scales, and by macroscopic study of pathological 
changes in liver and kidneys of animals.
Histological analysis. Obtained material was fixed 
in buffered 10% formalin with pH 7.4 and condensed 
in paraffin using histoprocessor Histos-5 (Milestone, 
Italy). From paraffin blocks, 5 micron thickness histo-
logical sections were prepared with the help of micro-
tome Microm HM325 (Thermo Scientific, Germany). 
Sections were stained with hematoxylin-eosin (H & E) 
for general assessment of tumor. Analysis of histologi-
cal response — treatment pathomorphosis in tumor 
tissues was carried out according to K.A. Galakhin 
method [11] by determining a relative part of viable 
tumor tissue (RPVTT) in percentage.
Immunohistochemical study of VEGF expression 
in the OT cells has been carried out using of mono-
clonal rat antibody specific to the VEGF — anti-VEGF 
Ab-1 RB-222 Polyclonal (Thermo Scientific, USA). For 
evaluation of VEGF expression were assessed by semi-
quantitative method via calculation of the number 
of positively stained cells in percentage [10].
Obtained results were studied and photographed 
using microscope Nikon Eclipse 80i with camera DS-
5SMc/L2 and optical magnification ×400.
Statistical analysis. Processing of the results 
of study has been carried out using program package 
Statistica 6.0. Parametric statistics including method 
of Student’s t-criterion was used. Survival of animals 
has been analyzed by Kaplan-Meier, log-rank criterion 
was used for paired comparisons, criterion χ2 — for 
multiple comparisons between groups. Data were 
considered statistically significant at р < 0.05.
RESULTS
In accordance with immunocytochemical study 
the grade of ERs and PRs expression in OT cells was 
high — 60% each.
Animals, which received combination of cisplatin 
and triptorelin (Group 1, P + T), and were euthanized 
on days 14, 17 and 19, had no ascites. No tumor le-
sions in abdominal cavity and pelvis were detected 
macroscopically. Omentum was lysed, single papillary 
inclusions on serous tissues of intestine and in ovaries 
were observed in one of 3 rats. Other 4 rats, which 
died in later terms of observation (Table 2), had serous 
or hemorrhagic ascites. The volume of ascitic liquid has 
constituted 10.1 ± 5.3 ml and was lower as compared 
with the same in animals, which received cisplatin, 
triptorelin or exemestane monotherapy [10]. Spread 
of tumor process and level of involvement of organs 
of abdominal cavity and pelvis were lower as compared 
with the same ones using cisplatin and hormonal drug 
monotherapy [10], distinctive feature — small size 
of ovaries with insignificant papillary inclusions, ova-
ries of two rats had no visual signs of tumor. Liver and 
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kidneys had no pathological changes. In one rat, which 
died after 60 days, liver decreased in size, had an ochre-
yellow tint, and was of flaccid consistency. Mean mass 
of spleen decreased on 28.5% (800.4 ± 7.2 mg) that was 
significantly lower as compared with weight of spleen 
in animals of the control group (р < 0.05) [10]. At the 
same time, this rate did not differ significantly from 
the same one in rats, which received cisplatin mono-
therapy [10]. Histological analysis has shown large 
areas of necrosis and hemorrhages, accumulation 
of fibrous masses in tumor lesion (Figure). Cellular 
compound of OT was characterized by significant poly-
morphism, with larger part of degenerating cells and 
cells with pyknotic nuclei. Only single cells with equally 
stained cytoplasm and large round nuclei have been 
found. Mean RPVTT and VEGF expression in lesions 
of adenocarcinoma overgrowths were significantly low 
(10.1 ± 0.1 and 21.4 ± 1.4%, respectively) as compared 
with the same ones in OT of rats in control group and ani-
mals treated by monotherapy with cisplatin, triptorelin 
and exemestane (р < 0.01, р < 0.01, р < 0.01, р < 0.01, 
respectively) [10] (Table 3). Besides, significantly high 
survival of animals of this group has been observed 
as compared with the same one in rats, which were 
administered monotherapy using cisplatin, triptorelin 
and exemestane and the animals in the control group 
(р < 0.01, р = 0.01, р = 0.01, р < 0.01, respectively) [10]. 
At the same time, increase of life-span (ILS) has consti-
tuted 213.8%. Two animals (22.2%) have been treated 
and are still alive (545 days) without any signs of disease 
(see Table 2).
Table 2. Survival rates of rats with transplantable OT
Groups 
of animals
ILS, 
% MLS, days
Min 
LL, 
days
Max LL, 
days
OS,
%
Cured 
animals
n %
Group 1 
(P + Т)
n=9 (100%)
213.9* 43.0 (147.2)***±11.3 16 88 (545)*** 100.0 2 22.2
Group 2 
(P + Е)
n=9 (100%)
205.8** 41.9 (75.8)***±10.0 16 86 (365)*** 85.7±13.2 1 11.1
Group 3 
(P + Т + Е)
n=9 (100%)
40.1 19.2±1.3 16 27 44.3±15.4 0 0
Group 4 
(Т + Е)
n=9 (100%)
31.4 18.0±1.7 15 26 32.2±14.0 0 0
Note: ILS — increase of life-span; Max LL — maximal length of life; Min LL — 
minimal length of life; MLS — mean of life-span; OS — overall survival; *li-
ving rats with life-span more than 545 days have not been taken into ac-
count; **euthanized rat with 365 day life-span has not been taken into ac-
count; ***calculations with living rats of group 1 and one euthanized rat 
of group 2 are indicated in brackets.
Animals, which received combination of cisplatin 
and exemestane (Group 2, P + E) and were euthanized 
on days 14, 17, 19, had no ascites, the same as in rats 
of group 1. Macroscopic assessment has detected insig-
nificant tumor lesions in omentum and uterine append-
ages. At the same time, ovaries were small in size as com-
pared with the same ones in animals of the control group 
and in rats treated by cisplatin [10]. Rats, which have died 
in later terms of observation, had hemorrhagic ascites. 
The volume of ascitic liquid has constituted 8.0 ± 1.2 ml. 
Among rats which died, two rats had no visual signs 
of tumor involvement in abdominal cavity organs and 
pelvis. In other three animals, which have died on days 53; 
85 and 86 of observation, spread and level of involvement 
of internals in tumor process were significantly lower 
as compared with the same ones in rats, which received 
cisplatin monotherapy [10] and identical as compared 
with the animals which were administered a combina-
tion of cisplatin and triptorelin.  However, ovaries in these 
died rats had form of solid tumor as compared to ever-
ting papillary tumors, which were observed in animals 
of group 1, and also in rats treated by monotherapy and 
in the animals of the control group [10]. During visual 
assessment of liver and kidneys in all rats of this group, 
flaccid consistency and slight ochre-yellow coloration 
of the liver were observed in 2 ani mals and their kidneys 
had yellow specks on incision. Decrease of spleen weight 
has constituted 29.3% that had no significant differences 
as compared with the same one in rats, which received 
cisplatin monotherapy [10]. Histological study of ade-
nocarcinoma overgrowths has determined widespread 
necrosis, as well as significant inflammatory infiltration, 
hemorrhages, multiple lesions of angiomatosis and fibro-
sis (see Figure). Among necrosis lesions, fibrous layers 
have been determined, sometimes with hyalinosis and 
myxomatosis. Mean RPVTT has constituted 16.2 ± 0.3%, 
VEGF expression was low (15.0 ± 1.3%) (see Table 3). 
Statistical analysis has determined significant differences 
between these indices as compared with the same ones 
in OT of rats of group 1, in animals treated by mono-
therapy and in rats of the control group (р < 0.01) [10]. 
When analyzing the results in Table 2, we have deter-
mined significantly high survival of animals of this group 
as compared with the same one in rats of the control 
group and animals which received monotherapy using 
triptorelin and exemestane (р = 0.02, p = 0.04, p = 0.03, 
respectively) [10]. However, survival rates of animals 
in group 2 were higher as compared with the same ones 
in rats treated with cisplatin [10], and lower as compared 
with animals of group 1. At the same time, statistical sig-
nificance of such differences has not been determined 
(р = 0.08 and р = 0.4, respectively). ILS of animals of this 
group has constituted 205.8%. One rat (11.1%) has been 
treated, but on the day 365, a tumor in the right breast 
was detected in this rat. Autopsy of euthanized animal 
has not determined macroscopically and histologically 
any pathological changes considering organs of chest, 
abdominal cavity, pelvis and retroperitoneal space. 
Tumor in the right breast, 4.0×3.5 cm in size, has been 
found — histologically fibroadenoma.
Table 3. Antitumor effectiveness and toxic effect of treatment drugs 
in different combinations by RPVTT, VEGF expression in cells of OT and 
change of spleen weight in rats with transplantable OT
Groups of animals RPVTT, % VEGF, % Spleen weight decrease, %
Group (С), n = 9 50.1 ± 1.6 77.8 ± 2.8 –
Group 1 (P+Т), n = 7 10.1 ± 0.1* 21.4 ± 1.4* 28.5*
Group 2 (P+Е), n = 8 16.2 ± 0.3* 15.0 ± 1.3* 29.3*
Group 3 (P + Т + Е), n = 9 10.1 ± 0.3* 9.4 ± 1.8* 38.7*
Group 4 (Т + Е), n = 9 22.1 ± 0.4* 12.2 ± 0.9* 13.6
Note: Group (С) — rats of control group; *p < 0.05 in comparison with 
the control group [10].
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Rats treated with combination of cisplatin + triptore-
lin + exemestane (Group 3, P + Т + Е) and euthanized 
on days 14, 17 and 19, also had no ascites, the same 
as animals of groups 1 and 2. Macroscopic assess-
ment of abdominal cavity organs and pelvis has not 
shown tumor lesions, but ovaries of two rats had single 
tumor papillary inclusions with hemorrhages. Animals, 
which have died in later terms of observation, had 
hemorrhagic ascites. The volume of ascitic liquid has 
constituted 6.5 ± 1.5 ml and was lower as compared 
with the same one in rats of groups 1–2, in animals 
of the control group and rats treated using cisplatin, trip-
torelin and exemestane monotherapy [10]. The fact was 
interesting that in all died animals, no tumor changes 
of abdominal cavity organs and pelvis were found, 
ovaries were atrophic. However, liver enlargement, its 
flaccid consistency and ochre-yellow coloration have 
been detected in all rats of this group. Kidneys were 
also enlarged, flaccid, of grey color with yellow specks 
on incision and their cortical layer was dilated with signs 
of swelling. Decrease of spleen weight was the high-
est (38.7%) as compared with the same rate in rats 
of groups 1–2 and in animals which received cisplatin 
in monotherapy [10], but differences between them had 
no significance (р > 0.05) (see Table 3). Histological 
analysis has shown significant degenerative-necrotic 
changes in OT, which were similar to those in animals 
of group 1 and rats treated by cisplatin [10] (see Fi-
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Figure. Morphological and immunohistochemical picture in ovaries of rats with transplantable OT of groups 1–4. The highest 
rates of treatment pathomorphosis (RPVTT) in OT were noticed in the rats of group 1 (combination of cisplatin and triptorelin) and 
group 3 (combination of cisplatin + triptorelin + exemestane) (р < 0.05), whereas the highest expression of VEGF in cells of OT has 
been observed in the animals of groups, where the combination of triptorelin and exemestane was used — 3 (р < 0.05) and 4 (sig-
nificant differences in the level of VEGF expression in OT of this group as compared with rats of group 1, and lack of significance 
of such differences — with rats of groups 2–3)
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gure). RPVTT has constituted 10.1 ± 0.3%. This rate was 
the same as one in rats, which received combination 
of cisplatin and triptorelin, however, when compared 
with RPVTT of animals, which were treated in regimen 
of cisplatin monothe rapy (11.7 ± 0.2%) [10], statisti-
cal analysis has demonstrated significant diffe rences 
between mentioned rates (р < 0.01) (see Table 3). 
Expression of VEGF in tumor cells was the lowest (9.4 ± 
1.8%) and was significantly different as compared with 
the same in OT in rats of other groups (р < 0.01). 
 However, survival rates among rats of this group turned 
out to be significantly lower, than in animals of groups 
1 and 2 (р < 0.01), and had no significant differences 
as compared with the same rates in rats which were 
administered cisplatin, triptorelin and exemestane 
monotherapy [10] (р > 0.05) (see Table 2). At the same 
time, these rates were significantly higher as compared 
with survival rates in animals of the control group [10] 
(р = 0.01). ILS of animals of this group has constituted 
40.1%. Obtained results of the study allow assu ming 
that in rats treated with combination of cisplatin + 
triptorelin + exemestane toxic dystrophy of liver and 
kidneys has been present with further development 
of acute hepatocellular and kidney failure, which was 
likely a direct cause of animals’ death.
In rats, which received combination of triptorelin 
and exemestane (Group 4, Т + Е), volume of ascitic 
liquid has constituted 15.2 ± 3.4 ml, and had no sig-
nificant differences as compared with the same one 
in animals treated with triptorelin or exemestane mono-
therapy [10]. Ascitic liquid was hemorrhagic and serous-
“lactic”. Macroscopic study of rats, which have been 
euthanized on days 14, 17, and of one rat, which died 
on day 15, demonstrated no tumor changes of the ab-
dominal wall, organs of abdominal cavity and pelvis. 
Atrophic changes in ovaries were determined and one 
of them had insignificant papillary tumor overgrowths. 
In other animals, spreading of tumor process in organs 
of abdominal cavity and pelvis has been observed and 
its extent correlated directly with terms of observation. 
At study of liver and kidneys, no pathological changes 
were determined. Decrease of spleen weight has 
constituted 13.6% that had no significant differences 
in respect to the same rate in rats of control group 
and animals, which received triptorelin or exemestane 
monotherapy [10]. Histological study has shown that 
spreading of tumor in organs, walls of abdominal cavity 
and pelvis, as well as sizes of tumor tissue in rats of this 
group were almost twice less, than in control animals, 
but larger, than in rats of those groups with cisplatin 
application [10]. In overgrowths of adenocarcinoma, 
large necrosis and hemorrhages were also observed. 
Multiple lesions with angiomatosis and strong fibrosis, 
which was found in uterus, tubes and mesentery of in-
testine, have been determined in ovaries. Viable cells 
of adenocarcinoma were quite large, had basophilic 
cytoplasm and large nuclei, some cells with lucid cy-
toplasm and vacuoles were determined among them, 
sometimes with strong pyknotic changes of nuclei. 
Mean RPVTT has constituted 22.5 ± 0.4%, this rate 
was significantly lower, than the same one in control 
animals and rats, which were treated in regimen of trip-
torelin or exemestane monotherapy [10] (р < 0.01), and 
significantly higher, than this rate in animals of those 
groups, where cisplatin was applied (р < 0.01). VEGF 
expression was low (12.2 ± 0.9%) in small areas of tumor 
cells, which were arranged by loci, but expression of this 
marker was not detected in the major part of cells (see 
Table 3). Statistical analysis has determined significant 
diffe rences in the level of VEGF expression in OT of this 
group as compared with rats of group 1, animals of con-
trol group and rats which received monotherapy using 
cisplatin, triptorelin and exemestane [10], and lack of sig-
nificance of such differences — with rats of groups 2–3. 
However, survival rates of animals of this group were not 
high (32.2 ± 14.0%), they were the same as rates in rats 
treated with triptorelin or exemestane monotherapy [10]. 
Moreover, there were no significant differences regarding 
the same rates in control animals [10] (р = 0.2). ILS has 
constituted 31.4% (see Table 2).
DISCUSSION
In the previous article [10], we have analyzed 
the correlation between level of treatment pathomor-
phosis (RPVTT), expression of VEGF in cells of OT and 
life-span of animals. Inverse correlation between 
survival of animals and rate of RPVTT in OT (r = −0.3, 
р < 0.01), as well as direct correlation between RPVTT 
and expression of VEGF in tumor cells (r = 0.7, р < 0.01) 
have been determined [10]. At the same time, no cor-
relation has been found between survival of animals 
and VEGF expression in OT (r = −0.2, р = 0.11) [10]. 
Data of correlation analysis have proved such vari-
able histological, immunohistochemical rates and 
the results of survival of animals treated with different 
treatment drugs and their combinations.
Thus, as it has been stated before [10], represented 
model of transplantable OT, with positive hormonal re-
ceptor status and VEGF hyperexpression, had aggressive 
clinical course that has been confirmed by histological 
and immunohistochemical tests, as well as survival 
rates of animals. Obtained data have demonstrated ef-
fectiveness of cytostatic and hormonal drugs in mono-
therapy [10] and in different combinations. We have 
shown that not only cytostatic agent — cisplatin, but also 
hormonal drugs — triptorelin and exemestane in mono-
therapy have caused histological response — treatment 
pathomorphosis in OT that allows us to judge indirectly 
about antiproliferative and apoptotic activity of these 
agents [12–15]. Among the animals treated  using 
monotherapy with cisplatin, triptorelin or exemestane, 
the most pronounced antiangiogenic activity in OT has 
been observed after administration of hormonal drugs, 
however, the highest treatment pathomorphosis (RPVTT) 
in OT was in treatment with cisplatin [10].
The most pronounced antiangiogenic activity 
in OT cells has been determined in animals treated with 
combination of hormonal drugs triptorelin and exemes-
tane. At the same time, level of treatment pathomor-
phosis of tumor and rates of survival of these rats had 
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no significant differences as compared with the same 
ones in animals treated with triptorelin or exemestane 
monotherapy [10]. For this reason, combination of these 
hormonal drugs has not shown advantages of their ap-
plication in monotherapy regimen.
Combination of cytostatic agent with triptorelin 
or exemestane has shown significantly high rates 
of treatment pathomorphosis and antiangiogenic 
activity in OT, as well as the highest survival of ani-
mals as compared with the same one in rats treated 
in regimen of cisplatin, triptorelin, exemestane mono-
therapy [10] or combination of hormonal drugs.
We have noticed that hormonal drugs had no reli-
ably significant toxic effect as compared with cytostatic 
agent [10], and combination of cisplatin and triptorelin, 
cisplatin and exemestane did not exceed significantly 
toxic impact of cisplatin alone.
In animals, which received combination of three 
drugs, significantly highest antiangiogenic activity 
and high grade of treatment pathomorphosis have 
been observed. It was similar to the same one in rats 
treated with cisplatin and triptorelin, but animals 
have died from toxic hepatorenal failure. These data 
are the evidence of necessity of the further studies 
for mechanisms of potentiating mutual toxic effect 
of combination of cisplatin, triptorelin and exemestane 
depending on tolerable and treatment doses.
The most important result of the study consists 
in the fact that among animals, which received a combina-
tion of cytostatic agent with triptorelin or exemestane, three 
of them were treated (Р + Т — 22.2%, Р + Е — 11.1%).
Thus, triptorelin and exemestane increase antitu-
mor activity of cisplatin in the respect of transplantable 
malignant ascites OT and significantly increase sur-
vival of animals, especially when used in combination 
of cisplatin and triptorelin.
This is our first experimental study in vivo with 
application of hormonal drugs in monotherapy and 
in combination with the cytostatic agent on the model 
of transplantable malignant ascites estrogen and 
progesterone receptor-positive OT. The results ob-
tained demand necessity and perspective to continue 
experimental studies in vitro and in vivo with the aim 
to investigate the mechanisms of hormonal-receptor 
signals realization in the cells of OC under the effect 
of different sex hormones and to study the mecha-
nisms of increasing antitumor effect of cisplatin with 
triptorelin and exemestane. This will probably discover 
new opportunities for clinical approbation of hormonal 
therapy use, particularly in the combinations above, 
in the primary complex treatment of OC patients.
CONCLUSIONS
Combination of cytostatic drug with triptorelin 
or exemestane has demonstrated significantly high 
rates of treatment pathomorphosis and antiangiogenic 
activity in OT, as well as the highest survival in ani-
mals as compared with one in rats treated in regimen 
of monotherapy with cisplatin, triptorelin, exemestane 
or by combination of hormonal drugs.
Triptorelin and exemestane increase antitumor ac-
tivity of cisplatin in regard to transplantable malignant 
ascites OT and significantly increases survival of ani-
mals, especially when used in combination of cisplatin 
and triptorelin.
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